- Home
- TOVX vs THAR Comparison
TOVX vs THAR Comparison
Compare TOVX & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- THAR
- Stock Information
- Founded
- TOVX 2001
- THAR 2017
- Country
- TOVX United States
- THAR United States
- Employees
- TOVX N/A
- THAR N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- THAR Health Care
- Exchange
- TOVX Nasdaq
- THAR Nasdaq
- Market Cap
- TOVX 4.7M
- THAR 4.0M
- IPO Year
- TOVX 2006
- THAR 2022
- Fundamental
- Price
- TOVX $1.18
- THAR $1.25
- Analyst Decision
- TOVX Strong Buy
- THAR Strong Buy
- Analyst Count
- TOVX 1
- THAR 1
- Target Price
- TOVX $6.00
- THAR $17.00
- AVG Volume (30 Days)
- TOVX 23.5K
- THAR 135.3K
- Earning Date
- TOVX 05-06-2025
- THAR 05-08-2025
- Dividend Yield
- TOVX N/A
- THAR N/A
- EPS Growth
- TOVX N/A
- THAR N/A
- EPS
- TOVX N/A
- THAR N/A
- Revenue
- TOVX N/A
- THAR N/A
- Revenue This Year
- TOVX N/A
- THAR N/A
- Revenue Next Year
- TOVX N/A
- THAR N/A
- P/E Ratio
- TOVX N/A
- THAR N/A
- Revenue Growth
- TOVX N/A
- THAR N/A
- 52 Week Low
- TOVX $1.03
- THAR $1.14
- 52 Week High
- TOVX $12.25
- THAR $6.99
- Technical
- Relative Strength Index (RSI)
- TOVX 44.04
- THAR 33.84
- Support Level
- TOVX $1.08
- THAR $1.20
- Resistance Level
- TOVX $1.21
- THAR $1.47
- Average True Range (ATR)
- TOVX 0.07
- THAR 0.16
- MACD
- TOVX 0.00
- THAR -0.01
- Stochastic Oscillator
- TOVX 57.89
- THAR 20.04
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.